Glutathione has a unique ability to bind to toxins and helps the body excrete these substances
We focus on their latent applications in conditions including psoriasis, inflammatory bowel disease (IBD), rheumatoid arthritis (RA), asthma, multiple sclerosis (MS), Sjgrens syndrome (SS), and systemic lupus erythematosus (SLE), highlighting the broader therapeutic benefits of GLP-1RAs beyond their well-established use in managing T2DM and obesity
"Plus, part of the take-home from our abstract is that this is preventable
It shows 30-50% decreases in new and recurrent CUD in patients with diabetes or obesity who were treated with semaglutide vs non-GLP-1 medications
Mounjaro/Zepbound (tirzepatide), approved dual GLP-1/GIP agonist for type 2 diabetes and obesity Recent Highlights: In April 2026, the FDA approved orforglipron (Foundayo), making it one of the first oral GLP-1 pills that can be taken any time of day and that has no food or water restrictions
BPC 157 time dependently activated the VEGFR2-Akt-eNOS signaling pathway which could also be suppressed by dynasore